Hyperfine (NASDAQ:HYPR) versus Lifeward (NASDAQ:LFWD) Head to Head Review

Lifeward (NASDAQ:LFWD) and Hyperfine (NASDAQ:HYPR) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, institutional ownership, earnings and risk.

Volatility & Risk

Lifeward has a beta of 0.39, suggesting that its stock price is 61% less volatile than the S&P 500. Comparatively, Hyperfine has a beta of 1.41, suggesting that its stock price is 41% more volatile than the S&P 500.

Profitability

This table compares Lifeward and Hyperfine’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lifeward	-141.28%	-235.86%	-81.72%
Hyperfine	-210.75%	-97.88%	-61.81%

Analyst Ratings

This is a summary of current recommendations for Lifeward and Hyperfine, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifeward	1	1	2	0	2.25
Hyperfine	1	1	3	0	2.40

Lifeward presently has a consensus target price of $10.00, suggesting a potential upside of 43.68%. Hyperfine has a consensus target price of $2.03, suggesting a potential upside of 163.11%. Given Hyperfine’s stronger consensus rating and higher possible upside, analysts plainly believe Hyperfine is more favorable than Lifeward.

Earnings and Valuation

This table compares Lifeward and Hyperfine”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifeward	$22.03 million	0.89	-$19.91 million	($16.82)	-0.41
Hyperfine	$11.40 million	7.19	-$35.57 million	($0.38)	-2.03

Lifeward has higher revenue and earnings than Hyperfine. Hyperfine is trading at a lower price-to-earnings ratio than Lifeward, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

26.8% of Lifeward shares are owned by institutional investors. Comparatively, 15.0% of Hyperfine shares are owned by institutional investors. 1.5% of Lifeward shares are owned by company insiders. Comparatively, 26.3% of Hyperfine shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Hyperfine beats Lifeward on 9 of the 14 factors compared between the two stocks.

About Lifeward

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke. The company markets and sells its products directly to institutions and individuals, as well as through third-party distributors. The company was formerly known as Argo Medical Technologies Ltd. ReWalk Robotics Ltd. was incorporated in 2001 and is headquartered in Yokneam Illit, Israel.

About Hyperfine

Hyperfine, Inc., a medical device company, provides magnetic resonance imaging (MRI) products in the United States. The company offers Swoop Portable MR imaging system, which offers portable brain neuroimaging; and support and technical assistance services. It serves ICU, comprehensive, and primary stroke accredited facilities through direct sales and distributors. Hyperfine, Inc. was founded in 2014 and is based in Guilford, Connecticut.